ArticleThe oncologist2023

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Taito Fukushima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.